Effects of Alendronate on Bone Mineral Density in Men with Prostate Cancer Treated with Androgen Deprivation Therapy

Journal of Clinical Densitometry

Volumn 9, Issue 4, 2006, Pages 431-437

  Bruder, Jan M ^a   Ma, J Z ^a   Wing, N ^a   Basler, J ^b   Katselnik, D ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

bisphosphonates; hypogonadism; men; Osteoporosis; prostate cancer

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMUR NECK; HIP; HUMAN; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSTATE CANCER; RADIUS; SPINE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ALENDRONATE; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; DENSITOMETRY, X-RAY; HUMANS; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 33750607172     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2006.07.005     Document Type: Article

References (26)

1. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
2. Stoch S.A., Parker R.A., Chen L., et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86 (2001) 2787-2791
3. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., and Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urology 163 (2000) 181-186
4. Kiratli Bj., Srinivas S., Perkash I., and Terris M.K. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57 (2001) 127-132
5. Wei J.T., Gross M., Jaffe C.A., Gravlin K., Lahaie M., Gaerber G.J., and Cooney K.A. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. J Urology 54 (1999) 607-611
6. Suzuki Y., Aikawa K., Oishi Y., et al. A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)-the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate. Nippon Hinyokika Gakkai Zasshi 12 (1998) 961-966
7. Smith M.R., McGovern F.J., Zeitman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
8. Mittan D., Miller E., Basler J., Lee S., and Bruder J.M. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87 (2002) 3656-3661
9. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of Zolendronic Acid to prevent bone loss in men receiving androgen deprivation therapy for non metastatic prostate cancer. J Urol 169 (2003) 2008-2012
10. Diamond T.H., Winters J., Smith A., De Souza P., Kersley J.H., Lynch W.J., and Bryant C. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92 6 (2001) 1444-1450
11. Greenspan S.L., Coates P., Sereika S.M., Nelson J.B., Trump D.L., and Resnick N.M. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90 12 (2005) 6410-6417
12. Orwoll E., Ettinger M., Stuart W., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 (2000) 604-610
13. Ringe J.D., Faber H., and Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86 11 (2001) 5252-5255
14. The WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (1994), World Health Organization, Geneva
15. Faulkner K.G., and Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 5 (2002) 87-93
16. Leib E.S., Lewiecki E.M., Binkley N., and Hamdy R.C. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 7 (2004) 17-26
17. Looker A.C., Orwoll E.S., Johnston Jr. C.C., et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12 11 (1997) 1761-1768
18. Smith M.R., Fallon M.A., Lee H., and Finkelstein J.S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 3841-3846
19. Bruder J.M., Basler J., and Welch M.D. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen deprivation therapy. Urology 67 (2006) 152-155
20. Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int 75 (2004) 100-109
21. McClung M.R., Wasnich R.D., Hosking D.J., et al. Prevention of postmenopausal bone loss-six year results from the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 89 10 (2004) 4879-4885
22. Body J.J., Gaich G.A., Scheele W.H., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87 10 (2002) 4528-4535
23. Melton L.J., Atkinson E.J., O'Connor M.K., O'Fallon W.M., and Riggs B.L. Bone density and fracture risk in men. J Bone Miner Res 13 (1998) 1915-1923
24. Tucci J.R., Tonino R.P., Emkey R.D., Peverly C.A., Kher U., and Santora II A.C. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101 (1996) 488-501
25. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. [see comments]. Lancet 348 (1996) 1535-1541
26. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. [see comments]. JAMA 280 (1998) 2077-2082